The week that went by saw NASH drug stocks back in focus as positive results from a phase II study of Galmed Pharmaceuticals Ltd.'s (GLMD) investigational drug Aramchol seems to have had a positive rub off impact. Aramchol is being developed for treatment of patients with biopsy proven non-alcoholic steatohepatitis, or NASH.
Original Article: An Ear To The Pharma: 5 Stocks To Watch (OBSV, GERN, SRPT.)